Biomarker Signatures Predict Aging Health Quality
|
By LabMedica International staff writers Posted on 17 Jan 2017 |
A panel of 19 biomarkers in the blood was utilized to create molecular signatures that are able to predict how well an individual is aging and how severe the likelihood that he or she will develop an aging-related disease.
To establish these signatures, investigators at Boston University measured 19 blood biomarkers that included constituents of standard hematological measures, lipid biomarkers, and markers of inflammation and frailty in 4704 participants of the Long Life Family Study (LLFS). The biomarkers were selected based upon their noted quantitative change with age and specificity for inflammatory, hematological, metabolic, hormonal, or kidney functions.
The LLFS is a family-based study that enrolled 4935 participants including subjects and siblings (30%), their offspring (50%), and spouses (20%), with ages between 30 and 110 years. Approximately 40% of enrolled participants were born before 1935 and had a median age at enrollment of 90 years and 45% participants were male. Almost 55% of participants from the subject generation (birth year prior to 1935) have died since enrollment, with a median age at death of 96 years. Mortality in the generation born after 1935 is lower (3%) and among these few that have died, median age at death is currently 69 years.
The investigators used an agglomerative algorithm to analyze distribution of the 19 biomarkers and then grouped LLFS participants into clusters that yielded 26 different biomarker signatures.
To test whether these signatures were associated with differences in biological aging, the investigators correlated them with longitudinal changes in physiological functions and incident risk of cancer, cardiovascular disease, type II diabetes, and mortality using longitudinal data collected in the LLFS. One signature was found to be associated with significantly lower mortality, morbidity, and better physical function relative to the most common biomarker signature in LLFS, while nine other signatures were associated with less successful aging, characterized by higher risks for frailty, morbidity, and mortality.
"Many prediction and risk scores already exist for predicting specific diseases like heart disease," said first author Dr. Paola Sebastiani, professor of biostatistics at Boston University. "Here, though, we are taking another step by showing that particular patterns of groups of biomarkers can indicate how well a person is aging and his or her risk for specific age-related syndromes and diseases. These signatures depict differences in how people age, and they show promise in predicting healthy aging, changes in cognitive and physical function, survival, and age-related diseases like heart disease, stroke, type II diabetes, and cancer."
The study was published in the January 6, 2017, online edition of the journal Aging Cell.
To establish these signatures, investigators at Boston University measured 19 blood biomarkers that included constituents of standard hematological measures, lipid biomarkers, and markers of inflammation and frailty in 4704 participants of the Long Life Family Study (LLFS). The biomarkers were selected based upon their noted quantitative change with age and specificity for inflammatory, hematological, metabolic, hormonal, or kidney functions.
The LLFS is a family-based study that enrolled 4935 participants including subjects and siblings (30%), their offspring (50%), and spouses (20%), with ages between 30 and 110 years. Approximately 40% of enrolled participants were born before 1935 and had a median age at enrollment of 90 years and 45% participants were male. Almost 55% of participants from the subject generation (birth year prior to 1935) have died since enrollment, with a median age at death of 96 years. Mortality in the generation born after 1935 is lower (3%) and among these few that have died, median age at death is currently 69 years.
The investigators used an agglomerative algorithm to analyze distribution of the 19 biomarkers and then grouped LLFS participants into clusters that yielded 26 different biomarker signatures.
To test whether these signatures were associated with differences in biological aging, the investigators correlated them with longitudinal changes in physiological functions and incident risk of cancer, cardiovascular disease, type II diabetes, and mortality using longitudinal data collected in the LLFS. One signature was found to be associated with significantly lower mortality, morbidity, and better physical function relative to the most common biomarker signature in LLFS, while nine other signatures were associated with less successful aging, characterized by higher risks for frailty, morbidity, and mortality.
"Many prediction and risk scores already exist for predicting specific diseases like heart disease," said first author Dr. Paola Sebastiani, professor of biostatistics at Boston University. "Here, though, we are taking another step by showing that particular patterns of groups of biomarkers can indicate how well a person is aging and his or her risk for specific age-related syndromes and diseases. These signatures depict differences in how people age, and they show promise in predicting healthy aging, changes in cognitive and physical function, survival, and age-related diseases like heart disease, stroke, type II diabetes, and cancer."
The study was published in the January 6, 2017, online edition of the journal Aging Cell.
Latest Molecular Diagnostics News
- New Library Normalization and Amplification Tools Support Oncology Sequencing
- Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
- Statistical Method Improves Detection of Low-Level Cancer DNA in Blood Samples
- AI Tool Improves Accuracy of Cancer Liquid Biopsy for Therapy Selection
- Targeted RNA Test Enhances Genetic Diagnosis in Exome Sequencing
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- Study Highlights Inherited Breast Cancer Risk Genes in Young Black Women
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
Channels
Clinical Chemistry
view channel
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more
Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








